HK Stock Market Move | China XLX FERT(01866) rose over 6% in early trading, will distribute year-end dividends at the end of next month, with a dividend payout ratio increasing significantly to 44%.
China Xinli Xin Chemical (01866) rose nearly 6% in early trading, as of the time of writing, up 5.18% to HK$10.15, with a turnover of HK$139.5 million.
CHINA XLX FERT (01866) rose nearly 6% in the morning session, as of the time of writing, up 5.18% to HK$10.15, with a trading volume of HK$139.502 million.
In terms of news, CHINA XLX FERT will officially distribute a year-end dividend of RMB 0.32 per share on July 28, an increase of 23% year-on-year. It is worth noting that the dividend payout ratio has increased significantly from 23% in 2024 to 44%. The company has maintained annual cash dividends for six consecutive fiscal years since 2020, with the overall dividend per share showing an upward trend.
It is worth noting that the major shareholders of CHINA XLX FERT have recently been actively increasing their holdings. In late May, Chairman Liu Xingxu made five consecutive purchases of CHINA XLX FERT, buying a total of 4.094 million shares at a cost of approximately HK$43 million, increasing his stake to 32.70%; on June 4, Executive Director Yan Yunhua purchased 600,000 shares, spending nearly HK$6 million; on June 5, Yan Yunhua once again acquired 312,000 shares at a cost of approximately HK$3.05 million.
Related Articles

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

SEACON (02409) subsidiary enters into a vessel time charter arrangement with Zhejiang Shipping (Singapore)
RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

SEACON (02409) subsidiary enters into a vessel time charter arrangement with Zhejiang Shipping (Singapore)

RECOMMEND





